Biswanath Majumder
Overview
Explore the profile of Biswanath Majumder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Majumder B, Nataraj N, Maitreyi L, Datta S
Front Immunol
. 2024 Aug;
15:1414376.
PMID: 39100682
Mismatch repair proficient (MMRp) tumors of colorectal origin are one of the prevalent yet unpredictable clinical challenges. Despite earnest efforts, optimal treatment modalities have yet to emerge for this class....
2.
Patnam S, Majumder B, Joshi P, Singh A, Nagalla B, Kumar D, et al.
ACS Pharmacol Transl Sci
. 2024 Jan;
7(1):137-149.
PMID: 38230292
Glioblastoma multiforme (GBM) is the most aggressive type of glioma and is often resistant to traditional therapies. Evidence suggests that glioma stem cells (GSCs) contribute to this resistance. Mithramycin (Mit-A)...
3.
Mitra D, Saha D, Das G, Mukherjee R, Banerjee S, Alam N, et al.
iScience
. 2023 Dec;
26(12):108395.
PMID: 38047085
Triple-negative breast cancer (TNBC) is the most elusive subtype of breast cancer that encounters treatment dilemmas owing to the paucity of druggable targets. We found hyperactivation of c-MET and ephrin...
4.
Saha D, Mitra D, Alam N, Sen S, Mustafi S, Majumder P, et al.
J Cell Commun Signal
. 2022 Sep;
17(3):591-608.
PMID: 36063341
Vasculogenic mimicry (VM), defined as an endothelial cell independent alternative mechanism of blood and nutrient supply by dysregulated tumor cells, is associated with poor prognosis in oral squamous cell carcinoma...
5.
Saha D, Mitra D, Alam N, Sen S, Mustafi S, Mandal S, et al.
Int J Exp Pathol
. 2022 Feb;
103(2):54-64.
PMID: 35170826
Vasculogenic mimicry (VM), an endothelial cell-independent alternative mechanism of blood supply to the malignant tumour, has long been considered as an adverse prognostic factor in many cancers. The correlation of...
6.
Ray S, Saha D, Alam N, Mustafi S, Mandal S, Sarkar A, et al.
Int J Exp Pathol
. 2021 Mar;
102(2):80-92.
PMID: 33655604
A high incidence of oral squamous cell carcinoma (OSCC) is observed in South-East Asian countries due to addictions such as chewing tobacco. Local invasion and distant metastases are primary causes...
7.
Smalley M, Przedborski M, Thiyagarajan S, Pellowe M, Verma A, Brijwani N, et al.
iScience
. 2020 Jun;
23(6):101229.
PMID: 32554190
Ex vivo human tumor models have emerged as promising, yet complex tools to study cancer immunotherapy response dynamics. Here, we present a strategy that integrates empirical data from an ex ...
8.
Mitra D, Bhattacharyya S, Alam N, Sen S, Mitra S, Mandal S, et al.
Breast Cancer Res Treat
. 2019 Nov;
179(2):359-370.
PMID: 31686261
Purpose: The occurrence of vasculogenic mimicry (VM) and EphA2-mediated tumour progression are associated with poor prognosis in various solid tumours. Here, we aimed to investigate the prognostic implications of VM...
9.
Das U, Manna K, Adhikary A, Mishra S, Das Saha K, Sharma R, et al.
Free Radic Res
. 2019 Oct;
53(9-10):944-967.
PMID: 31576765
The major drawback of anticancer therapy is the development of resistance against drugs and radiation at the later phase of treatment which may lead to recurrences of the disease. Therefore,...
10.
Goldman A, Khiste S, Freinkman E, Dhawan A, Majumder B, Mondal J, et al.
Sci Signal
. 2019 Aug;
12(595).
PMID: 31431543
Metastable phenotypic state transitions in cancer cells can lead to the development of transient adaptive resistance or tolerance to chemotherapy. Here, we report that the acquisition of a phenotype marked...